Table 1.
Mean (SD) | BF10 | Duration | |||||
---|---|---|---|---|---|---|---|
Prop | Placebo | t | U | r (BF10) | tau (BF10) | ||
Baseline measures | |||||||
Age | 21.65 (2.78) | 22.10 (1.92) | 0.33 | 0.34 | 0.01 (0.16) | 0.02 (0.17) | |
LSASAvoid | 21.35 (9.66) | 21.35 (9.60) | 0.28 | 0.29 | 0.20 (0.53) | 0.13 (0.50) | |
LSASFear | 27.63 (9.81) | 25.65 (10.54) | 0.34 | 0.36 | 0.28 (1.59) | 0.19 (1.53) | |
ASI | 17.05 (8.11) | 18.10 (9.42) | 0.30 | 0.28 | −0.04 (0.17) | −0.03 (0.17) | |
PRPSA | 138.33 (9.20) | 138.70 (9.49) | 0.28 | 0.28 | 0.09 (0.20) | 0.03 (0.18) | |
STAI-S | 43.55 (8.61) | 40.25 (9.68) | 0.58 | 0.62 | 0.05 (0.17) | 0.04 (0.18) | |
STAI-T | 43.30 (6.98) | 45.50 (11.71) | 0.39 | 0.64 | −0.04 (0.17) | −0.04 (0.18) | |
PHQ-9 | 4.00 (2.62) | 3.95 (2.65) | 0.28 | 0.26 | 0.12 (0.25) | 0.10 (0.31) | |
RSES | 19.20 (3.84) | 19.70 (5.45) | 0.30 | 0.32 | −0.10 (0.21) | −0.07 (0.23) | |
STAI-S S2 | 38.65 (10.77) | 41.05 (10.75) | 0.36 | 0.36 | NA | NA | |
Additional single items | |||||||
Confidence | 6.15 (1.72) | 6.25 (1.94) | 0.28 | 0.32 | −0.03 (0.16) | −0.02 (0.17) | |
RuminationWait | 55.80 (25.36) | 61.95 (24.00) | 0.39 | 0.32 | 0.46 (123.92) | 0.32 (95.32) | |
RuminationDay | 42.93 (24.77) | 38.75 (24.88) | 0.32 | 0.35 | 0.33 (3.72) | 0.22 (3.38) | |
Versus expected | −17.78 (45.38) | −21.53 (41.82) | 0.30 | 0.29 | −0.11 (0.23) | −0.06 (0.22) | |
Versus expectedAbsolute Score | 39.17 (28.40) | 37.88 (26.77) | 0.30 | 0.34 | 0.01 (0.17) | −0.02 (0.18) |
BF10 Bayes Factor for difference between groups/relationship with Duration, prop Propranolol group, r Pearson’s r, SD standard deviation, t Bayesian independent samples’ t test, tau Kendall’s tau, U Bayesian Mann–Whitney U test, LSAS Liebowitz Social Anxiety Scale, ASI anxiety sensitivity index, PRPSA personal report of public speaking anxiety, STAI-S/T state-trait anxiety inventory—state/trait, PHQ-9 patient health questionnaire 9, RSES Rosenberg Self-esteem Scale.